Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: J Neuroophthalmol. 2019 Jun;39(2):191–199. doi: 10.1097/WNO.0000000000000760

Figure 5. ST266 treatment reduces demyelination in the optic nerve during EAE optic neuritis.

Figure 5.

(A) Optic nerves from PBS- (N=9) and HSA-treated EAE (N=9) mice showed significant (*p<0.05) levels of demyelination compared with controls (N=5). EAE mice that received either once (N=9) or twice (N=9) daily doses of intranasal ST266 from days 15 to 30, showed a trend toward, but no significant, attenuation of demyelination. EAE mice that received either once (N=9) or twice (N=9) daily intranasal doses of ST266 continuously from day 15 to 56 showed a significant reduction of demyelination scores compared to PBS- or HSA-treated EAE mice (@p<0.05). (B) Representative images of LFB stained optic nerves images from each group show the relative level of myelin staining (original magnification X20).